Ignite Creation Date:
2025-12-24 @ 2:59 PM
Ignite Modification Date:
2026-01-03 @ 8:45 PM
Study NCT ID:
NCT04076059
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-10-24
First Post:
2019-08-19
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Sponsor:
Astellas Pharma China, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-09-11
Start Date Type:
ACTUAL
Primary Completion Date:
2022-11-18
Primary Completion Date Type:
ACTUAL
Completion Date:
2028-12-31
Completion Date Type:
ESTIMATED
First Submit Date:
2019-08-19
First Submit QC Date:
None
Study First Post Date:
2019-09-03
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2023-10-30
Results First Submit QC Date:
None
Results First Post Date:
2023-11-18
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-10-23
Last Update Post Date:
2025-10-24
Last Update Post Date Type:
ESTIMATED